Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 05, 2019 09:00 ET | Source: MannKind

MannKind and One Drop Sign Collaboration Agreement to Integrate Bluetooth-Connected Inhaler with Dose Detection into the One Drop Platform

WESTLAKE VILLAGE, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) and One Drop today announced that they have signed a collaborative agreement that is intended to...
August 01, 2019 17:02 ET | Source: MannKind

MannKind Corporation to Hold 2019 Second Quarter Financial Results Conference Call on August 7, 2019

WESTLAKE VILLAGE, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) will release its 2019 second quarter and year-to-date financial results and its management will host a...
July 31, 2019 09:00 ET | Source: MannKind

Afrezza® Safety and Pharmacokinetics Study in Pediatric Patients Opens Enrollment for Cohort 3

WESTLAKE VILLAGE, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that the Afrezza® safety and pharmacokinetics study in pediatric patients is now...
July 18, 2019 08:52 ET | Source: MannKind

MannKind Repays Maturing Debt Obligation; Buys Back Certain Warrants

WESTLAKE VILLAGE, Calif., July 18, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced the repayment of outstanding debt by an aggregate amount of approximately $4.0 million...
July 15, 2019 09:00 ET | Source: MannKind

MannKind Partners with GoodRx to Help Raise Awareness on Reducing Out of Pocket Insulin Cost for Patients

More than 65,000 patients pay over $200 per month for their mealtime insulinCommercially insured patients can pay as little as $15 per month for inhaled insulinUnderinsured and uninsured patients can...
July 11, 2019 16:14 ET | Source: MannKind

MannKind Expands Commercial Scale Manufacturing Capabilities for High-Potency Molecules

WESTLAKE VILLAGE, Calif., July 11, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for...
June 12, 2019 09:00 ET | Source: MannKind

MannKind to Present at the JMP Securities Life Sciences Conference

WESTLAKE VILLAGE, Calif., June 12, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for...
June 09, 2019 14:00 ET | Source: MannKind

MannKind Presents Positive Afrezza® Clinical Data from Three Studies at ADA 79th Scientific Sessions

WESTLAKE VILLAGE, Calif., June 09, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that new data from three different studies of Afrezza® (insulin human) Inhalation Powder...
June 03, 2019 08:00 ET | Source: MannKind

Pó para inalação Afrezza® (insulina humana) aprovado no Brasil

WESTLAKE VILLAGE, Califórnia e BELO HORIZONTE, Brasil, June 03, 2019 (GLOBE NEWSWIRE) -- A MannKind Corporation (Nasdaq:MNKD) e a BIOMM SA (BVMF:BIOM3) anunciaram hoje que o Pó para Inalação...
June 03, 2019 08:00 ET | Source: MannKind

Afrezza® (insulin human) Inhalation Powder Approved in Brazil

WESTLAKE VILLAGE, Calif. and BELO HORIZONTE, Brazil, June 03, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) and BIOMM SA (BVMF:BIOM3) today announced that Afrezza® (insulin human)...